10x Genomics and Harvard University have sued Element Biosciences, alleging that Element’s AVITI24
multiomics platform, Teton chemistry, and related services infringe on four university-owned patents exclusively licensed by the genomics and sequencing tools giant—while Element has denied wrongdoing and promises to fight the lawsuit.
At issue are four patents—three of which cover technologies related to methods of analyzing the nucleic acids of a cell, awarded between 2021 and 2023, and all titled, “Compositions and methods for analyte detection”: U.S. Patent Nos. 11,021,737 (‘737), 11,566,276 (‘276), 11,566,277 (‘277).
The fourth patent in question, U.S. Patent No. 12,264,358 (‘358), covers methods of selectively sequencing amplicons in a biological sample, and was awarded in April 2025 under the title, “Method of selectively sequencing amplicons in a biological sample.”
“Element’s employees, customers, collaborators, and partners have practiced and continue to practice (with Element’s knowledge) one or…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
